Login to Your Account

Medicines Co. fends off Mylan's Angiomax ANDA

By Michael Fitzhugh
Staff Writer

Tuesday, October 28, 2014
A U.S. court cleared a major generic threat to The Medicines Co.'s top-seller, Angiomax (bivalirudin), ruling Monday that Mylan Inc.'s abbreviated new drug application (ANDA) infringed on a patent protecting the anticoagulant through 2028.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription